RT Journal Article
SR Electronic
T1 The Association of Lymphocyte count and levels of CRP, D-Dimer, and LDH with severe coronavirus disease 2019 (COVID-19): A Meta-Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.20.20072801
DO 10.1101/2020.04.20.20072801
A1 Ali, Almigdad H. M.
A1 Mohamed, Sagad Omer Obeid
A1 Elkhidir, Ibrahim H. E.
A1 Elbathani, Mohamed Elata Hassan
A1 Ibrahim, Abazr A. H.
A1 Elhassan, Almutasim B. E.
A1 Salman, Mohammed Suliman Tawer
A1 Elhassan, Mazin A.M.
A1 Elnil, Mahmoud
A1 Abuzied, Abdelhamid Ibrahim Hassan
YR 2020
UL http://medrxiv.org/content/early/2020/04/24/2020.04.20.20072801.abstract
AB The rapid progression of Coronavirus disease 2019 (COVID-19) and its increasing burden on health systems necessitate the identification of parameters of severe infection to help in monitoring, prognoses and development of treatment algorithms. This review aims to investigate the association of lymphocyte count, CRP, LDH, and D-Dimer with the severe form of COVID-19. This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The databases of MEDLINE/PubMed, WHO-Virtual Health Library (VHL), and ScienceDirect were used for the systematic search. Random effects model was used to estimate the pooled standardized mean differences (SMD) with the corresponding 95% confidence interval (CI), using OpenMeta Analyst software. A total of 11 studies, with 2437 COVID-19 patients, which fulfilled the eligibility criteria were included in the meta-analysis. The analysis revealed that lymphocyte count was significantly lower in patients with the severe form of COVID-19 (SMD = - 1.025, P value <.001). Also, the analysis of SMD showed that patients with severe COVID-19 have a significantly higher serum levels of CRP (SMD = 3.363, P value <.001), D-Dimer (SMD = 1.073, P value <.001), and LDH (SMD = 3.345, P value <.001). Low lymphocyte count and high levels of CRP, LDH, and D-Dimer are associated with severe COVID-19. These laboratory markers could be used as clinical indicators of worsening illness and poor prognosis of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work didn’t receive any external fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable upon requestCOVID-19Coronavirus Disease 19SARS-Cov-2Severe Acute Respiratory Syndrome novel Coronavirus 2CRPC-Reactive ProteinLDHLactate Dehydrogenase